Effects of a natural ingredient-based vaginal gel on vaginal health

Submission date	Recruitment status No longer recruiting	Prospectively registered		
01/02/2017		□ Protocol		
Registration date	late Overall study status Completed Condition category	Statistical analysis plan		
15/02/2017		[X] Results		
Last Edited		Individual participant data		
14/11/2022	Urological and Genital Diseases			

Plain English summary of protocol

Background and study aims

Cervical ectopy is a benign (harmless) condition that causes the delicate cells that line the cervix (birth canal) to be found on the surface outside of the cervix. This can be caused by childbirth, sexual intercourse and birth control use. For the majority of women this does not cause any problems but it can lead to higher amounts of vaginal discharge (mucous) and to bleeding after sexual intercourse. In order for this condition to be treated, a colposcopy (a procedure where the inside of the cervix is examined using a special microscope with a light (a colposcope)) is used to freeze or cauterise (burn) the cells. However, the ectopic tissue can reoccur therefore alternative treatment can be helpful. Palomacare® is a gel which acts as a moisturiser and can help repair cells. This study evaluates if Palomacare® gel can help to treat cervical ectopy and improve vaginal health in women.

Who can participate? Women aged 18-45.

What does the study involve?

Participants attend a routine gynaecological visit (where they have a vaginal examination and colposcopy) and are then instructed on how to correctly use a vaginal gel called Palomacare® every day at bedtime for 12 days. Participants are followed up with a vaginal examination and colposcopy after 12 days to evaluate vaginal health.

What are the possible benefits and risks of participating?

Participants may benefit from improvements in their vaginal health. There are no notable risks to participants.

Where is the study run from? Instituto Palacios de Salud y Medicina de la Mujer (Spain)

When is the study starting and how long is it expected to run for? December 2014 to April 2015

Who is funding the study? Procare Health (Spain)

Who is the main contact? Dr Santiago Palacios

Contact information

Type(s)

Public

Contact name

Dr Josep Combalia

Contact details

Passeig del Ferrocarril 339 Castelldefels Spain 08060

Type(s)

Scientific

Contact name

Dr Santiago Palacios

ORCID ID

https://orcid.org/0000-0003-2229-1200

Contact details

Instituto Palacios de Salud y Medicina de la Mujer Antonio Acuña 9 Madrid Spain E-28009

Additional identifiers

Protocol serial number

Paloma15/1

Study information

Scientific Title

Beneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: A pilot study in asymptomatic women

Study objectives

The aim of this study is to assess the clinical benefits of Coriolus versicolor-based vaginal gel (Palomacare®) on epithelization of cervical lesions and to improve vaginal microbiota and vaginal health in asymptomatic healthy women.

Ethics approval required

Old ethics approval format

Ethics approval(s)

This study does not require ethical approval. According to Spanish regulations ethics approval is not required for studies with the following characteristics: real life, pilot study, with a medical device (not a drug) class I already marketed and used within approved indication, and sponsored by the principal investigator and not by a private pharmaceutical company.

Study design

Observational open-label single cohort prospective pilot clinical study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Asymptomatic women with ectopia and alterations of the vaginal microbiota

Interventions

Participants attend a routine gyneacological visit where they have a vaginal examination and a colposcopy to evaluate their symptoms. They are instructed on how to correctly use the vaginal gel Palomacare® once day at bedtime for 12 days.

Palomacare® is a non-hormonal (hyaluronic acid, ß-glucan, alpha-glucan oligosaccharide, Coriolus versicolor, Asian centella, Azadirachta indica and Aloe vera) gel that acts a moisturiser and lubricant because of strong hydrating properties, also enhancing and accelerating repair of atrophic or injured cervicovaginal mucosa.

Participants are followed up 12 days after the treatment at the gyneacological with a vaginal examination and a colposcopy to assess their vaginal health and microbiota.

Intervention Type

Supplement

Primary outcome(s)

Degree of epithelization of the cervical mucosa is evaluated by standard colposcopy and rated by the the investigator using the ectopy ephithelization score at baseline and 12 days.

Key secondary outcome(s))

- 1. Vaginal microbiota is evaluated using the Vagina Status-Diagnostic test (Instiüt für Mikroökologie, Herborn, Germany) and further rated by the investigator using a 5-point Liker scale at baseline and 12 days
- 2. The vaginal health is assessed by the Bachmman Vaginal Health Index at baseline and 12 days

Completion date

01/04/2015

Eligibility

Key inclusion criteria

- 1. Women aged between 18 and 45 years old
- 2. No signs and symptoms of vaginal disease
- 3. Normal Papanicolaou smear

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Total final enrolment

21

Key exclusion criteria

- 1. Vaginal infections
- 2. Use of vaginal products other than the investigational compound
- 3. Being pregnant or breastfeeding.
- 4. History or concomitant diseases who are deemed to be ineligible by the investigator

Date of first enrolment

01/02/2015

Date of final enrolment

01/03/2015

Locations

Countries of recruitment

Spain

Study participating centre

Instituto Palacios de Salud y Medicina de la Mujer

C/ Antonio Acuña 9 Madrid Spain 28009

Study participating centre Clínica Sagrada Família

Torras i Pujalt, 1 Barcelona Spain 08022

Sponsor information

Organisation

Instituto Palacios de Salud y Medicina de la Mujer

ROR

https://ror.org/01kvepn75

Funder(s)

Funder type

Industry

Funder Name

Procare Health

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study is not expected to be made available due to confidentiality reasons.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type

Details

Results article		16/03/2017	29/01/2019 Yes	No
$\underline{\textbf{Participant information sheet}}$	Participant information sheet	07/02/2017	21/02/2017 No	Yes
Participant information sheet		11/11/2025	11/11/2025 No	Yes